Expanding spectrum of “spitzoid” lesions: a small series of 4 cases with MAP2K1 mutations
Open Access
- 11 October 2020
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 479 (1) , 195-202
Abstract
The molecular background of a significant proportion of spitzoid neoplasms is still unknown. Recently, activating mutations in MAP2K1 have been described in a few spitzoid lesions, but not in benign Spitz nevi. We report four cases of melanocytic tumors with spitzoid features in which a MAP2K1 mutation was detected. The lesions did not show a single distinct phenotype and ranged from benign to malignant. Two cases resembled desmoplastic Spitz nevi. Based on the combination of morphological, immunohistochemical, and molecular findings, one case was classified as benign, one as probably benign, possibly intermediate low-grade (MELTUMP—melanocytic tumor of unknown malignant potential), one case was classified as intermediate (MELTUMP), and one case was considered a superficial spreading melanoma with spitzoid features. Based on this, we conclude that MAP2K1 mutations can indicate a spitzoid genetic signature and can be found in both benign and malignant spitzoid neoplasms.Keywords
Funding Information
- Maastricht University Medical Center
This publication has 14 references indexed in Scilit:
- Combined activation of MAP kinase pathway and β-catenin signaling cause deep penetrating neviNature Communications, 2017
- Detection ofBRAF,NRAS,KIT,GNAQ,GNA11andMAP2K1/2mutations in Russian melanoma patients using LNA PCR clamp and biochip analysisOncotarget, 2017
- A review of kinase fusions in melanocytic tumorsLaboratory Investigation, 2017
- Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma PatientsClinical Cancer Research, 2015
- Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug ResistanceClinical Cancer Research, 2013
- High‐throughput sequencing of the melanoma genomeExperimental Dermatology, 2012
- MEK1 mutations confer resistance to MEK and B-RAF inhibitionProceedings of the National Academy of Sciences, 2009
- Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): Its usefulness as an adjunctive diagnostic tool for melanocytic tumorsJournal of Dermatological Science, 2005
- Genetic Changes in Neoplasms Arising in Congenital Melanocytic NeviThe American Journal of Pathology, 2002
- Mutations and Copy Number Increase of HRAS in Spitz Nevi with Distinctive Histopathological FeaturesThe American Journal of Pathology, 2000